Westlake Village biotech firm MannKind announced a direct-purchase program Jan. 16 that aims to provide its inhalable insulin product to consumers for as low as $4 per day. The lowered price goes to the first 1,000 customers to register for the program for the first 12 months, the company said. Additional participants beyond that will…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
